HC Wainwright Has Bearish Forecast for DNTH Q3 Earnings

Key Points

• HC Wainwright has lowered its Q3 2025 earnings per share estimate for Dianthus Therapeutics to ($0.99), down from ($0.97), while maintaining a "Buy" rating with a price target of $40.00.
• The company reported a Q2 loss of ($0.88) EPS, missing the consensus estimate of ($0.86) and generating revenue of only $0.19 million, significantly below the expected $0.87 million.
• Despite recent downgrades, the consensus opinion from seven analysts remains a "Buy" with a price target averaging $53.00 per share for Dianthus Therapeutics.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Stock analysts at HC Wainwright reduced their Q3 2025 earnings per share estimates for Dianthus Therapeutics in a report issued on Monday, August 11th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.99) per share for the quarter, down from their prior estimate of ($0.97). HC Wainwright has a "Buy" rating and a $40.00 price objective on the stock. The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.61) per share. HC Wainwright also issued estimates for Dianthus Therapeutics' Q4 2025 earnings at ($0.99) EPS, FY2025 earnings at ($3.88) EPS, Q1 2026 earnings at ($1.07) EPS, Q2 2026 earnings at ($1.20) EPS, Q3 2026 earnings at ($1.31) EPS, Q4 2026 earnings at ($1.34) EPS, FY2026 earnings at ($4.92) EPS, FY2027 earnings at ($4.51) EPS, FY2028 earnings at ($4.06) EPS and FY2029 earnings at ($0.96) EPS.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). The firm had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%.

Other analysts have also issued reports about the company. Robert W. Baird cut their price target on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. William Blair assumed coverage on Dianthus Therapeutics in a report on Wednesday, July 2nd. They issued an "outperform" rating on the stock. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $53.00.

Dianthus Therapeutics Price Performance

Shares of Dianthus Therapeutics stock opened at $19.90 on Wednesday. The firm has a market cap of $640.54 million, a price-to-earnings ratio of -6.12 and a beta of 1.43. The stock's 50-day moving average is $19.37 and its 200-day moving average is $20.01. Dianthus Therapeutics has a one year low of $13.36 and a one year high of $32.27.

Institutional Trading of Dianthus Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. US Bancorp DE raised its stake in Dianthus Therapeutics by 2,013.3% in the first quarter. US Bancorp DE now owns 1,585 shares of the company's stock valued at $29,000 after buying an additional 1,510 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of Dianthus Therapeutics in the fourth quarter valued at approximately $59,000. GAMMA Investing LLC grew its position in shares of Dianthus Therapeutics by 3,030.6% in the first quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock valued at $70,000 after purchasing an additional 3,758 shares during the last quarter. AlphaQuest LLC acquired a new position in shares of Dianthus Therapeutics in the second quarter valued at approximately $94,000. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Dianthus Therapeutics by 21.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,468 shares of the company's stock valued at $207,000 after purchasing an additional 1,647 shares during the last quarter. Institutional investors own 47.53% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.